[A19-84] Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V

Last updated 02.04.2020

Project no.:
A19-84

Commission:
Commission awarded on 27.09.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

First-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR-mutant or ALK-positive NSCLC

Result of dossier assessment:

Added benefit neither proven in PD-L1 expression (TPS) < 50% nor in PD-L1 expression (TPS) > 50%

Note:

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2020-01-02.

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Project no.	Title	Status
A19-83	Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V	Commission completed
A19-81	Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A17-52	Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A17-51	Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V	Commission completed
A18-88	Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)	Commission completed
A17-50	Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A19-86	Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A24-102	Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V	Commission work started
A24-97	Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V	Commission work started
A20-97	Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A22-67	Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V	Commission completed
A21-69	Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V	Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form